Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT)

Youn H Kim, MD, Richard T. Hoppe, MD, Alain H Rook, MD, Amit Maity, MD PhD, Larisa J Geskin, MD, David P Horowitz, MD, Genet Finnegan, MHS, PA-C, Michael Khodadoust, MD PhD, Wen-Kai Weng, MD PhD, Analuisa Lares, ANP, BSN, RN, Eric Ki Jun Hong, BS, Marie Buchanan, RN, Vernon Ma, BS, Hue Kha, BS, Chris E Lawrence, PhD, Vladimir Vainstein, MD, Lena A Basile, PhD JD

Blood (2016) 128 (22): 4165.

https://doi.org/10.1182/blood.V128.22.4165.4165

Published: 2016

Journal Articles

Recombinant Human IL-12 Exerts Differential Effects on Circulating CD56 bright and CD56 dim NK Cells in Healthy Human Subjects

Simmy Thomas, PhD, Chris E Lawrence, PhD, Vernon Mar, MS, Hue Kha, MS, Lena A Basile, PhD JD

Blood (2014) 124 (21): 756.

https://doi.org/10.1182/blood.V124.21.756.756

Published: 2014

Journal Articles

Recombinant Human IL-12 Promotes NK Cell Migration: Increased CXCL10, Co-Receptors IL-12Rβ2 and CXCR3, and Bright CD56 NK Cells In Healthy Human Subjects

Simmy Thomas, PhD, Chris E. Lawrence, PhD, Vernon Mar, MS, Hue Kha, MS, Vladimir Vainstein, MD, MS, Mamata Gokhale, PhD, Lena A. Basile, PhD, JD

Blood (2013) 122 (21): 3481.

https://doi.org/10.1182/blood.V122.21.3481.3481

Published: 2013

Journal Articles

XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell Malignancies

Chris E Lawrence, PhD, Jonathan Zalevsky, PhD, Holly Horton, PhD, Irene Leung, PhD, Seung Chu, PhD, Sher Karki, PhD, Eugene Zhukovsky, PhD, John R Desjarlais, PhD, David F Carmichael, PhD

Blood (2008) 112 (11): 2621.

https://doi.org/10.1182/blood.V112.11.2621.2621

Published: 2008

Journal Articles

Evaluation of the Pharmacokinetics, Immunogenicity, and Safety of XmAb®2513 in the Ongoing Study XmAb2513-01: A Phase 1 Study of Every Other Week XmAb2513 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

Anas Younes, MD, Jonathan Zalevsky, PhD, Kristie A. Blum, MD, Mitchell R Smith, MD, PhD, Henry C. Fung, MD, David A Ramies, MD, Chris E Lawrence, PhD, Daniel Combs, BS, Jeffrey Bloss, MD

Blood (2008) 112 (11): 5012.

https://doi.org/10.1182/blood.V112.11.5012.5012

Published: 2008

Journal Articles

XmAb™2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies.

Chris E. Lawrence, PhD, Phil W. Hammond, PhD, Jonathan Zalevsky, PhD, Holly Horton, PhD, Seung Chu, PhD, Sher Karki, PhD, John R. Desjarlais, PhD, David F. Carmichael, PhD

Blood (2007) 110 (11): 2340.

https://doi.org/10.1182/blood.V110.11.2340.2340

Published: 2007

NARROW

A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT)

Recombinant Human IL-12 Exerts Differential Effects on Circulating CD56 bright and CD56 dim NK Cells in Healthy Human Subjects

Recombinant Human IL-12 Promotes NK Cell Migration: Increased CXCL10, Co-Receptors IL-12Rβ2 and CXCR3, and Bright CD56 NK Cells In Healthy Human Subjects

XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell Malignancies

Evaluation of the Pharmacokinetics, Immunogenicity, and Safety of XmAb®2513 in the Ongoing Study XmAb2513-01: A Phase 1 Study of Every Other Week XmAb2513 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

XmAb™2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT)

Recombinant Human IL-12 Exerts Differential Effects on Circulating CD56 bright and CD56 dim NK Cells in Healthy Human Subjects

Recombinant Human IL-12 Promotes NK Cell Migration: Increased CXCL10, Co-Receptors IL-12Rβ2 and CXCR3, and Bright CD56 NK Cells In Healthy Human Subjects

XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell Malignancies

Evaluation of the Pharmacokinetics, Immunogenicity, and Safety of XmAb®2513 in the Ongoing Study XmAb2513-01: A Phase 1 Study of Every Other Week XmAb2513 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

XmAb™2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only